Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.930
+0.410 (9.07%)
At close: Feb 6, 2026, 4:00 PM EST
4.720
-0.210 (-4.26%)
After-hours: Feb 6, 2026, 7:51 PM EST
Immuneering Employees
Immuneering had 54 employees as of September 30, 2025. The number of employees decreased by 12 or -18.18% compared to the same quarter last year.
Employees
54
Change
-12
Growth
-18.18%
Revenue / Employee
n/a
Profits / Employee
-$1,157,340
Market Cap
318.33M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 54 | -12 | -18.18% |
| Jun 30, 2025 | 54 | -12 | -18.18% |
| Mar 31, 2025 | 54 | -11 | -16.92% |
| Sep 30, 2024 | 66 | -1 | -1.49% |
| Jun 30, 2024 | 66 | 0 | - |
| Mar 31, 2024 | 65 | -3 | -4.41% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Sep 30, 2023 | 67 | -7 | -9.46% |
| Jun 30, 2023 | 66 | -8 | -10.81% |
| Mar 31, 2023 | 68 | 0 | - |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Sep 30, 2022 | 74 | 38 | 105.56% |
| Jun 30, 2022 | 74 | 40 | 117.65% |
| Mar 31, 2022 | 68 | 36 | 112.50% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Sep 30, 2021 | 36 | 10 | 38.46% |
| Jun 30, 2021 | 34 | - | - |
| Mar 31, 2021 | 32 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 299 |
| AC Immune | 172 |
| Century Therapeutics | 150 |
| X4 Pharmaceuticals | 143 |
| Foghorn Therapeutics | 112 |
| PepGen | 57 |
| Atea Pharmaceuticals | 56 |
| Cybin | 50 |
IMRX News
- 4 weeks ago - Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data - Seeking Alpha
- 4 weeks ago - Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower - Benzinga
- 4 weeks ago - Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript - Seeking Alpha
- 4 weeks ago - Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire
- 6 weeks ago - Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - GlobeNewsWire
- 7 weeks ago - Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - GlobeNewsWire
- 7 weeks ago - Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - GlobeNewsWire
- 2 months ago - Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire